Compare PepsiCo, Inc. (PEP) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? PepsiCo, Inc. trades at $137.3 (market cap $188.97B), while Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B). The key difference: PepsiCo, Inc. is far larger — about 101.6× Recursion Pharmaceuticals Inc's market cap, and PepsiCo, Inc. pays a 4.28% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| PEP | RXRX | |
|---|---|---|
Market Cap | $188.97B | $1.86B |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $6.79 |
52-Week Low | $134.95 | $2.84 |
Enterprise Value | $231.47B | $1.38B |
Dividend Yield | 4.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $138.45, up 0.6% with bearish technical signals but strong fundamentals. The company reported consistent earnings beats in recent quarters with Q3 2026 results pending. Revenue grew to $93.93B in 2025, though net income declined to $8.24B. Analysts maintain a consensus price target of $158.79 with 33% buy ratings. Recent news highlights price adjustments on snack products and sponsorship changes.
PEP offers stable dividend income and moderate growth potential, but faces margin pressure from input costs and competitive pricing. The stock trades below analyst targets with solid cash flow generation, though technical indicators suggest near-term weakness. Key risks include consumer sensitivity to price increases and execution challenges in North American markets.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
